$ANRO News

Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36

Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $24

Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate

HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $50 Price Target

Alto Neuroscience Presents Data On Its Phase 2a Study Of ALTO-207 In Participants With Major Depressive Disorder At 2026 Annual Meeting Of Society Of Biological Psychiatry

Alto Neuroscience shares are trading lower. The company announced the initiation of a Phase 2b randomized placebo-controlled trial of ALTO-207 in treatment-resistant depression.

Alto Neuroscience shares are trading lower. The company announced the initiation of a Phase 2b randomized placebo-controlled trial of ALTO-207 in treatment-resistant depression.

Alto Neuroscience Advances ALTO-207 Into Phase 2b For Treatment-Resistant Depression; Targeting Accelerated Path To Registration

Alto Neuroscience Files Prospectus For Resale Of 6M Shares, Company To Receive Proceeds Only From Pre-Funded Warrants

Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $38

HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $50 Price Target

Jones Trading Maintains Buy on Alto Neuroscience, Lowers Price Target to $44

Wedbush Maintains Neutral on Alto Neuroscience, Lowers Price Target to $21

Alto Neuroscience shares are trading lower after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.

Alto Neuroscience shares are trading lower after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.

Alto Neuroscience Announces Topline Data From Phase 2 POC Clinical Trial Evaluating ALTO-101 For Treatment Of CIAS; ALTO-101 Did Not Achieve Statistical Significance On Primary EEG Or Cognitive Endpoints Versus Placebo

Alto Neuroscience (ANRO) Price Target Increased by 15.20% to 36.72

Baird Maintains Outperform on Alto Neuroscience, Raises Price Target to $41

Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $22

Alto Neuroscience shares are trading higher after the company reported better-than-expected Q4 EPS results.